title: [HIT-GBM: multicenter study of treatment of children with malignant glioma].
abstract: The German society for paediatric oncology and hematology starts a clinical study for the treatment of children with glioblastoma, multifocal astrocytoma grade 3, brain stem grade 3 astrocytoma and typical diffuse ponsglioma. Conventional fractionated radiotherapy (54 Gy) will follow surgery. Simultaneously an additional experimental treatment will be given. The experimental treatment study will change every second year and starts with oral trofosfamide 100 mg/m2/d and VP16 25 mg/m2/d.
authors.affiliation: Kinderkliniken der Universität Münster.
authors.forename: J E
authors.initials: JE
authors.lastname: Wolff
authors.forename: J
authors.initials: J
authors.lastname: Boos
authors.forename: J
authors.initials: J
authors.lastname: Kühl
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D002648:Child; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000031:analogs & derivatives; D005047:Etoposide / Q000008:administration & dosage; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D009367:Neoplasm Staging; D011149:Pons; D015996:Survival Rate
chemical_list: D018906:Antineoplastic Agents, Alkylating; D005047:Etoposide; D003520:Cyclophosphamide; C003726:trofosfamide